Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

ClinicalTrials.gov ID: NCT00865566

Public ClinicalTrials.gov record NCT00865566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men

Study identification

NCT ID
NCT00865566
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
2,504 participants

Conditions and interventions

Conditions

Interventions

  • DNA plasmid vaccine Biological
  • Recombinant adenoviral serotype 5 (rAD5) vector vaccine Biological
  • DNA vaccine placebo Biological
  • HIV-1 recombinant adenovirus vaccine placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
Male
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2009
Primary completion
Oct 5, 2017
Completion
Oct 5, 2017
Last update posted
Oct 14, 2021

2009 – 2017

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
18
Facility City State ZIP Site status
Alabama CRS Birmingham Alabama 35294
The AIDS Research Alliance of America CRS Los Angeles California 90015
UCLA CARE Center CRS Los Angeles California 90035
Bridge HIV CRS San Francisco California 94143
University of Colorado Hospital CRS Aurora Colorado 80045
Orlando Immunology Center CRS Orlando Florida 32803
The Hope Clinic of the Emory Vaccine Center CRS Decatur Georgia 30030
UIC Project WISH CRS Chicago Illinois 60612
VRC Clinical Trials Core CRS Bethesda Maryland 20816
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Boston Massachusetts 02115-6110
Fenway Health (FH) CRS Boston Massachusetts 02215-4302
NY Univ. HIV/AIDS CRS New York New York 10016
Columbia P&S CRS New York New York 10032-3732
New York Blood Center CRS New York New York 10065
University of Rochester Vaccines to Prevent HIV Infection CRS Rochester New York 14642
Case Clinical Research Site Cleveland Ohio 44106
Penn Prevention CRS Philadelphia Pennsylvania 19104
Vanderbilt Vaccine (VV) CRS Nashville Tennessee 37232-2582
University of Texas Southwestern CRS Dallas Texas 75235
Baylor Vaccine Research Center CRS Houston Texas 77030
Care-Id Crs Annandale Virginia 22003
Seattle Vaccine and Prevention CRS Seattle Washington 98109-1024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00865566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00865566 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →